Biotechnology is attracting increased investment as scientific advances create new ways to develop medicines, treat disease and address unmet healthcare needs. The sector is benefiting from several long-term drivers. Ageing populations, rising levels of chronic and complex diseases and continued demand for more effective treatments are increasing the need for new medical technologies and therapies.
At the same time, the science is changing quickly. Developments in areas including gene editing, RNA-based treatments, cell and gene therapies, precision medicine and artificial intelligence are expanding the range of treatments that biotechnology companies can develop.
For investors, the attraction is linked to the potential for scientific advances to create new products and new markets. A successful therapy can generate significant commercial value, particularly where it addresses a serious disease with limited existing treatment options.
However, biotech investment is also highly dependent on individual company and clinical outcomes. The sector has a wide gap between successful and unsuccessful programmes, meaning that scientific progress does not automatically translate into commercial returns.
Clinical trials are therefore a major source of risk and opportunity. Positive trial results can materially change expectations around a company’s prospects, while unsuccessful trials can significantly reduce the value of a development programme.
Regulatory approval is another key stage. Even promising treatments must demonstrate sufficient safety and efficacy before they can reach patients. Companies also need to establish manufacturing capacity, secure distribution and demonstrate that healthcare systems are willing to pay for their products.
The ability to finance development, manage clinical programmes, protect intellectual property and commercialise successful treatments can all affect the eventual value created.
AI can be used in drug discovery and development, potentially helping researchers analyse large datasets and identify potential drug candidates more efficiently. However, the technology remains part of a wider development process that still requires scientific validation, clinical testing and regulatory approval.
The structure of biotech financing is also changing. Partnerships between smaller biotechnology companies and larger pharmaceutical businesses can provide capital and development expertise, while acquisitions can give established pharmaceutical companies access to new medicines and technologies.
M&A is therefore an important part of the sector. Large pharmaceutical companies face the ongoing need to replenish their product pipelines as existing medicines approach the end of their patent protection. Smaller biotechnology businesses can provide access to new treatments and technologies that may otherwise take years to develop internally.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
